ライフサイエンスコーパス: vein

1 e perfusion of the hepatic artery and portal vein.

2 lasma samples usually taken from the cubital vein.

3 islets from BALB/c (H-2) mice via the portal vein.

4 acids are delivered to the liver via portal vein.

5 ost epithelial tissue and the hepatic portal vein.

6 tion, and the signal intensity in the portal vein.

7 tions/vein with mean PF times of <90 seconds/vein.

8 ion with monitoring of right upper pulmonary vein.

9 cavity along with thrombosis of left portal vein.

10 showed the presence of prominent superficial veins.

11 tally limited by effects from large draining veins.

12 characterized by a black ascocarp and white veins.

13 the JVP at the external and internal jugular veins.

14 and direct connections between arteries and veins.

15 BS) were injected into Balb/cj mice via tail veins.

16 dense network of arteries, capillaries, and veins.

17 t PS(plt) limits thrombin formation in large veins.

18 upper-extremity, renal, ovarian, or retinal veins.

19 ribed the widths, angles and connectivity of veins.

20 ule, tubules, arteries, arterial lumina, and veins.

21 ) for the arteries and 0.88 +/- 0.03 for the veins.

22 f NETs (20 uM ICG,) was IV injected via tail vein 1-hour prior to photoacoustic (PA) and fluorescence

23 Hundred percent of thoracic veins (25 of 25) were successfully isolated with 12.4+/-

24 d liver disease, progressive loss of central vein access, and repeated life-threatening central venou

25 rom the interstitial space back to the great veins, against an adverse pressure gradient.

26 e ultrasound imaging of the internal jugular vein also proved the validity of the proposed method.

27 number, location, and distance of the vortex vein ampullae from the center of optic nerve.

28 The number of discrete vortex vein ampullae that can be discerned by UWF ICGA in healt

29 ion, SHAPE data were collected from a portal vein and a hepatic vein, and the difference was compared

30 f statistics describing scale transitions in vein and areole geometry.

31 Levels of amino acids in the hepatic portal vein and caudal vein were measured at intervals after a

32 ndritic nature of the hepatic artery, portal vein and hepatic vein can be predicted, together with th

33 e was 28 mmHg, fundus exam revealed tortuous veins and a flame shaped hemorrhage at 7 o'clock.

34 s the temperature of structures such as wing veins and androconial organs.

35 weeks, respectively, to isolate 25 thoracic veins and create 5 right atrial (PF(LD)), 6 mitral (PF(H

36 eter can deliver focal PF to durably isolate veins and create linear lesions with excellent transmura

37 Patients with postthrombotic femoral veins and those who received multiple stents were charac

38 the gastric content, blood (portal and main veins) and urine of rats after an intragastric administr

39 e collected from a portal vein and a hepatic vein, and the difference was compared with HVPG measurem

40 over 20 mouse brains, with labeled arteries, veins, and capillaries according to their anatomical reg

41 teries) and intima thickness (%IT; arteries, veins, and indeterminate vessels) were calculated relati

42 ructures including the blood pool, pulmonary veins, and mitral valve.

43 he functional significance of different leaf vein architectures.

44 between vein grafts and arterial grafts when veins are used as a composite graft based on the interna

45 atibility, degree of HLA mismatch, number of veins/arteries, cold ischemia, and travel times.

46 We interpret the veins as being composed of carbonates, similar to those

47 , defined as the gradient between the portal vein at the site downstream of the site of obstruction a

48 In veins, between 9,052 and 10,744 m, within this gold zone

49 mmunicates with the intestine via the portal vein, biliary system, and mediators in the circulation.

50 the hepatic artery, portal vein and hepatic vein can be predicted, together with their geometrical f

51 rTM was administered into the jugular-vein catheter before or 6 h after MRSA inoculation, whil

52 lood samples were collected from the jugular-vein catheter before, 6 h and 12 h after MRSA inoculatio

53 Male Sprague-Dawley rats with jugular-vein catheterization were divided into three groups: no

54 sed on an endogenous pararetrovirus, petunia vein clearing virus (PVCV), because this virus may have

55 We observed blotched flowers and a vein-clearing symptom in aged petunia plants.

56 t to noise in the azygos vein, right hepatic vein, common bile duct, and superior mesenteric artery.

57 Artery-vein comparisons were made by estimating, in a pair of a

58 p learning model using preablation pulmonary vein computed tomography can be applied to predict the t

59 Among them, pulmonary vein computed tomography geometric slices from 358 patie

60 earning was applied to preablation pulmonary vein computed tomography geometric slices to create a pr

61 The accuracy of prediction in each pulmonary vein computed tomography image for NPV trigger was up to

62 velopment of enlarged, congestive submucosal veins could play a role in these late bleedings, and ant

63 ibing elongation ratios, circularity ratios, vein density, and minimum spanning tree ratios.

64 linkages vary with scale and are weak, with vein density, minimum spanning tree ratio, and circulari

65 proliferation and leaf growth, vascular and vein development, chloroplast development, and photosynt

66 no, Italy) via the existing right subclavian vein dialysis catheter because of stenosis in the superi

67 MRI in AVM size, feeding artery and draining vein diameter, and artifact score (P >.05 for all).

68 ng the number of PVs, accessory variants and veins, diameter and ostial shape, distance to the first

69 Abdominal ultrasonography and portal vein doppler ultrasonography were performed in19 patient

70 ard the oval fossa and right upper pulmonary veins draining beyond the cavoatrial junction on transes

71 del angiogenesis patterns of Human Umbilical Vein EC (HUVEC).

72 FX activation occurred on human umbilical vein EC surfaces without the addition of external coagul

73 RNA-Seq of primary cultured human umbilical vein ECs exposed to progressively increasing severity an

74 pression of a tagged EMCN in human umbilical vein ECs, we found that treatment with tumor necrosis fa

75 omy (0%, 3%, 4%, P < 0.001), need for portal vein embolization (5%, 9%, 9%, P = 0.001), preoperative

76 is retrospective study was to compare portal vein embolization (PVE) and radiologica simultaneous por

77 After portal vein embolization (PVE), 15% of patients remain ineligib

78 E) and radiologica simultaneous portohepatic vein embolization (RASPE) for future liver remnant (FLR)

79 idities, hepatic function, ASA class, portal vein embolization rate)(p > 0.05).

80 ascular occlusion (rate or duration), portal vein embolization, drain use, etc.)(p > 0.05).

81 een energy sources, point-by-point pulmonary vein encirclement was performed using biphasic PFA poste

82 ular interface composed of a human umbilical vein endothelial cell (HUVEC)-lined, perfusable, bioengi

83 tryptase-neutralizing mAb on human umbilical vein endothelial cell permeability were assayed using a

84 ng PolyRad were evaluated on human umbilical vein endothelial cells (HUVEC) in vitro.

85 regression in vivo and drove Human Umbilical Vein Endothelial Cells (HUVEC) tube regression and apopt

86 endothelial cells (MLEC) and human umbilical vein endothelial cells (HUVEC) with SHIP-1 knockdown wer

87 Using primary human umbilical vein endothelial cells (HUVECs) and aortic endothelial c

88 Cultured human umbilical vein endothelial cells (HUVECs) and SC cells were transd

89 when encapsulated along with human umbilical vein endothelial cells (HUVECs) in gelatin methacrylate

90 In human umbilical vein endothelial cells (HUVECs), the risk allele "C" is

91 s diminished in YY1-depleted human umbilical vein endothelial cells (HUVECs).

92 s promoted tube formation of human umbilical vein endothelial cells in vitro.

93 modeled in vitro by placing human umbilical vein endothelial cells into a hypoxic incubator (1% O2)

94 y in the R. conorii-infected human umbilical vein endothelial cells' secretome, 46 proteins were up-r

95 ing the secretome of primary human umbilical vein endothelial cells.

96 ifically upregulate VEGFA in human umbilical vein endothelial cells.

97 seismic period by analyzing extension quartz veins exposed around the Nobeoka Thrust, southwestern Ja

98 ugular foramen, through the internal jugular veins (extracardiac vagal stimulation [ECVS]), analyzing

99 ys before end-to-side carotid artery-jugular vein fistula creation and for up to 42 days after fistul

100 The poro-elastic model of extensional quartz vein formation indicates that the formation of extension

101 descolea has chloranthoid teeth and tertiary veins forming elongate areoles.

102 rritories and with %IT (r=-0.44, P=0.024) of veins from obstructed lung territories.

103 Electrically isolating the pulmonary veins from the left atrium by catheter ablation is super

104 Renal vein glycerol-3-phosphate (G-3-P) had the strongest corr

105 Stents Versus Bare Metal Stents in Saphenous Vein Graft Angioplasty; NCT01121224) prospective, double

106 Vein graft disease (VGD) and failure result from complex

107 rent practices for the prevention of VGD and vein graft failure.

108 -kappaB pathway may be beneficial to prevent vein graft inflammation and consequent failure.

109 tery bypass grafting and >1 target saphenous vein graft lesions were associated with increased target

110 trial (The Effect of Ticagrelor on Saphenous Vein Graft Patency in Patients Undergoing Coronary Arter

111 st-dilation has been advocated for saphenous vein graft percutaneous coronary intervention to decreas

112 A saphenous vein graft to an important or less important target did

113 Approximately 15% of saphenous vein grafts (SVGs) occlude during the first year after c

114 orted similar mid-term patency rates between vein grafts and arterial grafts when veins are used as a

115 est evidence on the utilization of saphenous vein grafts for CABG surgery and provide an overview of

116 itrus greening, potato zebra chip and tomato vein greening diseases.

117 The superior veins had a statistically significant greater mean dista

118 The superior veins had a statistically significant greater mean ostia

119 Aged, diseased, human saphenous vein (HSV) remnants obtained from patients undergoing co

120 ncers, suggesting a direct role in promoting vein identity.

121 ry open strategy by cut-down of the cephalic vein, if necessary enhanced by a modified Seldinger tech

122 ood from artery, coronary sinus, and femoral vein in 110 patients with or without heart failure to qu

123 ys and spleen after inoculation via the tail vein in a bacteremia mouse model.

124 amino acids over time in the hepatic portal vein in contrast to that of the non-selected strain.

125 -right shunt in 4 and unobstructed pulmonary veins in all patients.

126 struct small, medium, and large arteries and veins in the rat brain and revealed areas of lowest redi

127 gly influenced by the presence of cracks and veins in the rocks where fluids and resulting rock alter

128 extracting the JVP from the anterior jugular veins, in a contact manner.

129 In mice, tail-vein-injected LOXCAT lowered the circulating lactate:pyr

130 ion and hepatosplenic infiltration in a tail-vein-injected mouse model.

131 ith mismatch or H2HR vivo-morpholino by tail vein injection for 1 week.

132 formed in wild-type rats at 1 hour post tail vein injection of (64)Cu-DOTA-ECL1i.

133 ed in mouse CCA induced by hydrodynamic tail vein injection of notch intracellular domain (NICD) and

134 model of tyrosinaemia that hydrodynamic tail-vein injection of plasmid DNA encoding the adenine base

135 mice with HCC, induced by hydrodynamic tail vein injection of proto-oncogenes, enhanced HCC developm

136 tered either intravenously via retro-orbital vein injection or via intracranial transplantation can a

137 to colonize the lung when delivered via tail vein injection.

138 e time of liver injury via hydrodynamic tail-vein injection.

139 Mice were given hydrodynamic tail vein injections of clustered regularly interspaced short

140 Mice were given 1 or 2 tail-vein injections of TIMP-GLIA or control nanoparticles.

141 By performing hydrodynamic tail-vein injections, we tested the impact of altering a well

142 Pulmonary vein isolation (PVI) is an effective treatment strategy

143 CMR)-detected atrial fibrosis plus pulmonary vein isolation (PVI).

144 Patients were randomized to either pulmonary vein isolation alone (n = 148) or pulmonary vein isolati

145 patients who underwent cryoballoon pulmonary vein isolation alone, had an implantable loop recorder,

146 A lower rate of first-pass pulmonary vein isolation and a higher rate of acute pulmonary vein

147 stent AF who underwent cryoballoon pulmonary vein isolation and had an implantable loop recorder impl

148 ty and safety of (1) focal PF-based thoracic vein isolation and linear ablation, (2) combined PF and

149 recurrences compared with standard pulmonary vein isolation and nonpulmonary vein trigger ablation in

150 assigned to (1) standard ablation (pulmonary vein isolation and nonpulmonary vein trigger ablation) v

151 Procedural strategies beyond pulmonary vein isolation have failed to consistently improve resul

152 Pulmonary vein isolation is insufficient to treat all patients wit

153 Pulmonary vein isolation is the cornerstone of AF ablation, and me

154 vein isolation alone (n = 148) or pulmonary vein isolation plus renal denervation (n = 154).

155 alemate, safer, and more effective pulmonary vein isolation seems increasingly realistic.

156 tion is the dominant technique and pulmonary vein isolation the principal lesion set.

157 The pulmonary vein isolation therapy duration time (transpiring from f

158 AF, planned for first CLOSE-guided pulmonary vein isolation using a contact force radiofrequency cath

159 Pulmonary vein isolation was performed in 94.6% of de novo ablatio

160 whereas in the experimental group, pulmonary vein isolation was performed using high power (45 W).

161 c drugs (class I or III agents) or pulmonary vein isolation with a cryoballoon.

162 e been shown capable of performing pulmonary vein isolation, but not flexible lesion sets such as lin

163 After pulmonary vein isolation, electrogram and spatial information was

164 s) of which 3 had AF terminated on pulmonary vein isolation, leaving 27 patients that underwent STAR-

165 s reestablished by conversion of pericentral vein-juxtaposed glutamine synthetase (GS)(-) hepatocytes

166 Consequently, high rates of pulmonary vein-left atrium reconnections are consistently seen in

167 ood pressure (SBP), renal hypoxia, and renal vein levels of pro-inflammatory marker tumor necrosis-fa

168 Associating liver partition and portal vein ligation (PVL plus transection=ALPPS) or the additi

169 tial hepatectomy (PH), intraoperative portal vein ligation (PVL), and associated liver partition and

170 ), and associated liver partition and portal vein ligation for staged hepatectomy (ALPPS) show clinic

171 lmonary Vein (LSPV)> Left Inferior Pulmonary Vein (LIPV); p<0.001).

172 (RIPV); p=0.001 and Left Superior Pulmonary Vein (LSPV)> Left Inferior Pulmonary Vein (LIPV); p<0.00

173 The long saphenous vein (LSV) is commonly used as a conduit in coronary art

174 h the fully annotated cerebral vessel artery-vein maps from 60 patients.

175 ture studies including primary and secondary veins may uncover additional insights.

176 g) was delivered to zebrafish through caudal vein microinjection during distinct periods in early neu

177 We quantify vein networks for leaves of 260 southeast Asian tree spe

178 to enable multiscale quantification of leaf vein networks, facilitating the comparison across specie

179 etworks (CNNs) to automatically segment leaf vein networks.

180 Non-pulmonary vein (NPV) trigger has been reported as an important pre

181 entional treatments in patients with hepatic vein obstruction (Budd-Chiari Syndrome) and in those wit

182 stthrombotic, and 26 with nonthrombotic deep vein obstruction.

183 artery occlusion (CRAO) and central retinal vein occlusion (CRVO) as a complication of persistent hy

184 In the central retinal vein occlusion (CRVO) cohort, univariate and multivariat

185 ar oedema (CMO) secondary to central retinal vein occlusion (CRVO).

186 DMO) (542 cases, 66.0%), followed by retinal vein occlusion (RVO) (91 cases, 13.3%).

187 = 1063) were diagnosed with ME from retinal vein occlusion (RVO), diabetic retinopathy (DR; diabetic

188 imaging measures in a mouse model of retinal vein occlusion (RVO).

189 Study of Comparative Treatments for Retinal Vein Occlusion 2, and 88 participants randomized to obse

190 ension might be at higher risk for impending vein occlusion as shown in this case.

191 aphy angiography (OCTA) among branch retinal vein occlusion disease (BRVO) cases with macular edema (

192 Central retinal vein occlusion is a variable disease pattern.

193 Branch RVO and hemiretinal vein occlusion patients (n = 13) gained a median of +45

194 e Standard Care vs Corticosteroid in Retinal Vein Occlusion Study.

195 to-right interatrial shunt without pulmonary vein occlusion underwent covered stent exclusion using s

196 interatrial shunt without causing pulmonary vein occlusion was confirmed on follow-up imaging.

197 h both retinal artery occlusions and retinal vein occlusions are associated with increased age and ca

198 roke expertise, whereas treatment of retinal vein occlusions is provided by ophthalmologists.

199 Adjunctive vein of Marshall (VOM) ethanol infusion (VOM-Et) can fac

200 The vein of Marshall contains innervation and AF triggers th

201 DESIGN, SETTING, AND PARTICIPANTS: The Vein of Marshall Ethanol for Untreated Persistent AF (VE

202 (n = 158) or catheter ablation combined with vein of Marshall ethanol infusion (n = 185) in a 1:1.15

203 :1.15 ratio to accommodate for 15% technical vein of Marshall ethanol infusion failures.

204 /185) in the catheter ablation combined with vein of Marshall ethanol infusion group compared with 38

205 ong patients with persistent AF, addition of vein of Marshall ethanol infusion to catheter ablation,

206 Vein of Marshall ethanol was successfully delivered in 1

207 et al. screened plasma taken from the renal vein of patients undergoing cardiac catheterization and

208 s aureus (MRSA) was inoculated into the tail vein of rats.

209 Pancreatic cells were injected into the tail veins of mice, and lung metastases were quantified.

210 If the veins on Bennu are carbonates, fluid flow and hydrotherm

211 were randomly selected, and the arteries and veins on their CT scans were manually annotated by five

212 like stem cells, located around the central vein or distributed throughout the liver lobule and exhi

213 the Bachmann bundle (P=0.008) and pulmonary vein (P=0.020) areas.

214 t, they strikingly failed to form the caudal vein plexus (CVP).

215 pecially limited tissue volume due to portal vein pressure.

216 nonthermal ablation technology for pulmonary vein (PV) isolation in patients with atrial fibrillation

217 atomy to achieve acute and durable pulmonary vein (PV) isolation.

218 iver transplant recipients both pre- [portal vein (PV) sample] and post-(liver flush; LF) reperfusion

219 Pulmonary vein (PV) stenosis is a highly morbid condition that can

220 icardial connections (ECs) between pulmonary veins (PVs) and other anatomic structures may hinder PV

221 n 25 patients, acute PVI (96 of 96 pulmonary veins [PVs]; mean ablation time: 22 min; interquartile r

222 olation and a higher rate of acute pulmonary vein reconnection were recorded in the group 20 W/LSI 5.

223 g neonatal blood loss, whereas the umbilical vein remains patent longer.

224 The renal vein required reconstruction more often with right kidne

225 eater mean ostial diameter than the inferior veins (Right Superior Pulmonary Vein (RSPV)> Right Infer

226 d signal and contrast to noise in the azygos vein, right hepatic vein, common bile duct, and superior

227 monary Vein (RSPV)> Right Inferior Pulmonary Vein (RIPV); p=0.001 and Left Superior Pulmonary Vein (L

228 the inferior veins (Right Superior Pulmonary Vein (RSPV)> Right Inferior Pulmonary Vein (RIPV); p=0.0

229 tance to first bifurcation than the inferior veins (RSPV> RIPV; p=0.008 and LSPV> LIPV; p=0.038).

230 ena cava (SVC) and the right upper pulmonary vein (RUPV), which is no longer committed to the left at

231 Respiratory-resolved analyses of caval veins showed significantly increased net and peak flow i

232 Ablation of nonpulmonary vein sites is increasingly being recognized as an import

233 my line in two patients, superior mesenteric vein (SMV) thrombosis in two patients, and intraluminal

234 nd, NR2F2 was essential to directly activate vein-specific enhancers and their associated genes.

235 p F, member 2) sites were overrepresented in vein-specific enhancers, suggesting a direct role in pro

236 elated gene) at many of these sites to drive vein-specific gene expression.

237 pecificity for detection of thoracic central vein stenosis or occlusion.(C) RSNA, 2020See also the co

238 s for the treatment of patients with central vein stenosis.

239 directionally from granuloma to the central veins, suggested that substances released from schistoso

240 nal thoracic artery (RITA) and the saphenous vein (SV).

241 , peak E wave, and the presence of pulmonary vein systolic reversal.

242 s thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism (PE), is th

243 Deep vein thrombosis (DVT) is a common but unpredictable comp

244 The diagnosis of recurrent ipsilateral deep vein thrombosis (DVT) is challenging, because persistent

245 of them have proximal limb-threatening deep vein thrombosis (DVT).

246 dd-Chiari Syndrome) and in those with portal vein thrombosis (second section); and we briefly comment

247 Cannula-associated deep vein thrombosis after venovenous extracorporeal membrane

248 of posttransplant cure, extensive mesenteric vein thrombosis and intestinal infarction, total intesti

249 ncreatitis and is associated with splanchnic vein thrombosis and pancreatic head necrosis.

250 rs for stricture development were splanchnic vein thrombosis and pancreatic head parenchymal necrosis

251 eon General's Call to Action to Prevent Deep Vein Thrombosis and Pulmonary Embolism in 2008 has been

252 Deep vein thrombosis and pulmonary embolism, collectively def

253 es it the drug of choice for preventing deep vein thrombosis and pulmonary embolism.

254 ient (7.7%) had both cannula-associated deep vein thrombosis and pulmonary embolism.

255 eatment period or asymptomatic proximal deep-vein thrombosis at the end of treatment.

256 ymptoms plus imaging-confirmed proximal deep vein thrombosis but no chest imaging.

257 were qualitative differences such that deep vein thrombosis exclusively afflicted the immunosuppress

258 eculated that the underlying cause of portal vein thrombosis in our case was coronaviruses.

259 eading cause of maternal mortality, and deep vein thrombosis leads to maternal morbidity, with postth

260 tion induced femoral cannula-associated deep vein thrombosis more frequently than femorojugular cannu

261 ymptomatic or incidental acute proximal deep-vein thrombosis or pulmonary embolism to receive oral ap

262 n, or amputation for ischemia) and VTE (deep vein thrombosis or pulmonary embolism) were assessed.

263 Femoral deep vein thrombosis was diagnosed in 5 of 12 patients with R

264 Cannula-associated deep vein thrombosis was found in 75 patients (71.4%) despite

265 a femoral associated cannula-associated deep vein thrombosis was identified in 10 patients (76.9%), a

266 A jugular associated cannula-associated deep vein thrombosis was identified in seven patients (53.8%)

267 ata regarding the secondary causes of portal vein thrombosis were normal.

268 f rare subgroups of pediatric VTE (eg, renal vein thrombosis), and will be important to ultimately gu

269 or adverse cardiovascular events, splanchnic vein thrombosis, and bleeding in a cohort with cirrhosis

270 uch as ventilator-associated pneumonia, deep vein thrombosis, and pressure sores; and shortened the d

271 ncluding myocardial infarction, stroke, deep vein thrombosis, and pulmonary embolism.

272 patients had femoral cannula-associated deep vein thrombosis, and two had an oxygenator or pump throm

273 y infection, hemorrhage, renal failure, deep vein thrombosis, and uncontrollable intracranial hyperte

274 , acute RV dysfunction, with or without deep vein thrombosis, is more common, but acute LV systolic d

275 also contribute to the pathogenesis of deep vein thrombosis, myocardial infarction and stroke.

276 c venous thromboembolism was defined as deep vein thrombosis, pulmonary embolism, or both, diagnosed

277 osite of symptomatic distal or proximal deep-vein thrombosis, pulmonary embolism, or venous thromboem

278 ranging from repeated thrombophlebitis, deep vein thrombosis, pulmonary embolism, transitory ischemic

279 (76.9%) had isolated cannula-associated deep vein thrombosis, two patients (15.4%) had isolated pulmo

280 patients (84.6%) had cannula-associated deep vein thrombosis.

281 ent had central venous catheter-related deep vein thrombosis.

282 e liver cell necrosis, together with central vein thrombosis.

283 of infection and presenting with left portal vein thrombosis.

284 er change of complications related to portal vein thrombosis.

285 us sinus thrombosis, along with left jugular vein thrombosis.

286 femoral and jugular cannula-associated deep vein thrombosis.

287 he basal regions of leaflets, and finally in vein tissues at late leaf developmental stages.

288 ferent catheter positions were delivered per vein to achieve circular tissue contact, even if PV pote

289 he gastrointestinal tract through the portal vein to the liver.

290 rd pulmonary vein isolation and nonpulmonary vein trigger ablation in patients undergoing a first AF

291 n (pulmonary vein isolation and nonpulmonary vein trigger ablation) versus (2) standard ablation plus

292 th hepatocellular carcinoma (HCC) and portal vein tumor thrombosis (PVTT) is 2-6 months; conventional

293 The difference when the sampled uterine vein was ipsilateral to the placenta was 54.8 (IQR 37.1-

294 HAPE gradient between the portal and hepatic veins was in good overall agreement with the HVPG measur

295 acids in the hepatic portal vein and caudal vein were measured at intervals after a single force-fee

296 tages of a complete occlusion of the central vein, wich are subsumed under the term venous stasis ret

297 SCID-beige mice injected via the tail vein with ERK clones were employed to determine metastat

298 sfully isolated with 12.4+/-3.6 applications/vein with mean PF times of <90 seconds/vein.

299 rategy by primary puncture of the subclavian vein without routine sonographic guidance.

300 ECM) abnormalities, and dilated intrascleral veins, yet, no dilation of arteries or capillaries.